Abstract: A method for preparing an inhibited starch, wherein it comprises the steps of a) providing a slurry containing a granular starch obtained from a starch containing raw material, b) alkalizing the slurry by adding ammonia or by adding one or more compounds having the ability to release or produce ammonia in the slurry, c) adjusting the p H of the slurry to a value above 10.0, preferably up to 12.0, and d) adding at least one oxidant to the slurry for a reaction with said ammonia; or wherein steps b) and c) are replaced with the step of alkalizing the slurry directly to a p H between 0.0 and 12.0, and the step of adding chloramine or dichloramine to the slurry, and wherein step d) is omitted; or wherein step c) is replaced with the step of adjusting the p H of the slurry to a value of between 7.0 and 10.0, and wherein step d) is followed by a step of adjusting the p H of the slurry to a value above 10.0, preferably up to 12.

Abstract: This invention relates to delivery matrix compositions (e.g., dietary products or pharmaceuticals) and related methods. In particular, the disclosure relates to delivery matrix compositions that include temperature-dependent O/W emulsion complexes, low viscosity sheared fluid gels, and viscous hydrogels that can facilitate the delivery of a wide range of substances to the gastrointestinal tract (e.g., small intestine) of a subject.

Abstract: A quinoline derivative used for soft tissue sarcoma combination therapy, relating to a use of the quinoline derivative in combination with a second therapeutic drug to treat soft tissue sarcoma, wherein the second therapeutic drug may be a chemotherapy drug, a small molecule targeted anti-tumour drug or an immunotherapy drug. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

Abstract: An inorganic porous carrier including a linker of formula (1) and having mode diameter of 0.04 ?m to 1 ?m in a pore distribution and the density of voids having an opening area of 0.0025 ?m2 or more of 12 to 30 voids/?m2 [a bond * represents a linkage to the oxygen atom in a silanol group of an inorganic porous substance; n is an integer; R represents an alkyl group containing 3 to 10 carbon atoms which may optionally have a substituent such as an alkoxy group; and L represents a single bond; an alkylene group of 1 to 20 carbon atoms; or an alkylene group containing 2 to 20 carbon atoms containing —CH2-Q-CH2— group wherein Q selected from a group consisting of —O— etc. is inserted into at least one of —CH2—CH2— group constituting the alkylene group]; and a method for preparing a nucleic acid using the same.

Abstract: A composition and method of use thereof wherein the composition comprises one or more components capable of releasing an aldehyde, one or more anticoagulants or chelating agents, and one or more polysaccharides. The composition has a pH of from about 4 to about 6.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Disclosed are a new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically disclosed are a compound represented by formula (II), pharmaceutically acceptable salts thereof, and isomers thereof.

Abstract: The present invention has objects to provide a novel crystalline 2-O-?-D-glucosyl-L-ascorbic acid and method for producing the same. The present invention solves the above objects by providing crystalline potassium salt of 2-O-?-D-glucosyl-L-ascorbic acid and method for producing the same.

Abstract: This invention relates to the isolation, concentration and/or purification of ribonucleic acid (RNA) in aqueous two-phase phase systems. In some embodiments, the present invention provides sample preparation methods, compositions and kit components for the isolation, concentration and/or purification of RNA from fluid mixtures comprising biological materials.

Abstract: There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic ? cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Abstract: A composition including anethole trithione or a derivative thereof of formula (I), sulfobutyl ether-beta-cyclodextrin and optionally a co-solvent, wherein the ratio of the sulfobutyl ether-beta-cyclodextrin to the compound of formula (I) ranges from 10 to 400, preferably from 57 to 200. Also, the use of the composition as a drug, namely for the treatment and/or the prevention of free oxygen radical-related diseases. Further, a kit-of-parts and/or a medical device including the composition. Lastly, a method for solubilizing a compound of formula (I) in an aqueous medium.

Abstract: A method and composition for enhancing synthesis of adenosine triphosphate (ATP) in mitochondria of brain cells of a human includes providing the composition including a synergistic compound of choline cation and succinate anion (2-) in a molar ratio of choline:succinate of 2:1 in the form of dicholine succinate (DiSu) in a daily dosage that synergistically increases ATP levels in brain cells. The method and composition are formulated to affect frequency and/or severity of various conditions by regulating ATP levels in brain cells. The method and composition are formulated to reduce rate of decline in the brain under conditions of cerebral hypoxia, e.g., due to aging, injury, illness, and the similar conditions.

Abstract: The present invention relates to methods for processing plant and/or micro-organism derived cellulose materials into rheology/structuring agents. More in particular, the present invention relates to methods wherein plant and/or micro-organism derived cellulose material is co-processed with carboxycellulose. The methods of the present invention provide a variety of benefits, in terms of process efficiency and scalability as well as in relation to the properties of the materials that are obtainable using these methods. For instance, it has been found that (highly) concentrated products produced using the method of the invention are easily (re)dispersible in water and aqueous systems to regain much of the cellulose component's original rheological performance.

Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Abstract: Disclosed are a cyclic dinucleotide prodrug molecule, a preparation method therefor and an application thereof relating to the field of pharmaceuticals. The cyclic dinucleotide prodrug molecule has a structure shown in formula I, II, or III, can freely cross cell membranes and release cyclic dinucleotide, and has high cell activity.

Abstract: The present invention relates to a veterinary composition comprising an iron complex as a sole active ingredient and a water-soluble polymer. The invention further relates to the use of such composition for controlling iron deficiencies and/or anaemic states in a non-human mammal.

Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

Abstract: Provided is a method of reducing a number of viable microbes, including contacting microbes with an antibiotic compound and applying pulses of electricity having a duration of between about 50 nanoseconds and about 900 nanoseconds. The pulses of electricity may have an intensity between about 20 kV/cm and about 40 kV/cm. The pulses of electricity may be applied at a frequency of between about 0.1 Hz and about 10 Hz. The microbes may be a gram-negative or a gram-positive strain of bacteria and the antibiotic may be applied at a concentration for a duration, wherein applying the antibiotic to the strain at the concentration for the duration does not reduce a viable number of bacteria of the strain as much, or at all, when the pulses of electricity are not also applied.

Abstract: A method of single-stranded RNA purification comprising the steps applying a sample containing single-stranded RNA to a solid phase bearing dominantly or exclusively primary amino groups on its surface, at a pH value sufficient to bind at least predominantly the single-stranded RNA, eluting the single-stranded RNA from the surface of the solid phase by exposing the surface of the solid phase to increasing pH.

Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.